Drug Profile
Research programme: mesenchymal stem cells therapeutics - Mesoblast
Alternative Names: Fucosylated mesenchymal lineage adult stem cells; Fucosylated MLCsLatest Information Update: 21 Sep 2023
Price :
$50
*
At a glance
- Originator Mesoblast
- Class Stem cell therapies
- Mechanism of Action Inflammation mediator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 1 diabetes mellitus
Most Recent Events
- 21 Sep 2023 Discontinued - Preclinical for Type 1 diabetes mellitus in USA (unspecified route)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA
- 17 Mar 2016 Mesoblast in-licenses ex vivo fucosylation technology from Harvard Medical School